[go: up one dir, main page]

NO20054631L - Antistoff mot tumorspesifikt antigen som mal - Google Patents

Antistoff mot tumorspesifikt antigen som mal

Info

Publication number
NO20054631L
NO20054631L NO20054631A NO20054631A NO20054631L NO 20054631 L NO20054631 L NO 20054631L NO 20054631 A NO20054631 A NO 20054631A NO 20054631 A NO20054631 A NO 20054631A NO 20054631 L NO20054631 L NO 20054631L
Authority
NO
Norway
Prior art keywords
cancer
template
antibody against
specific antigen
tumor specific
Prior art date
Application number
NO20054631A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054631D0 (no
Inventor
Shuji Takahashi
Kimihisa Ichikawa
Toshinori Agatsuma
Keisuke Fukuchi
Takehiro Hirai
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO20054631D0 publication Critical patent/NO20054631D0/no
Publication of NO20054631L publication Critical patent/NO20054631L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20054631A 2003-03-10 2005-10-07 Antistoff mot tumorspesifikt antigen som mal NO20054631L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003063648 2003-03-10
PCT/JP2004/003048 WO2004081050A1 (ja) 2003-03-10 2004-03-09 癌特異的抗原を標的とした抗体

Publications (2)

Publication Number Publication Date
NO20054631D0 NO20054631D0 (no) 2005-10-07
NO20054631L true NO20054631L (no) 2005-12-09

Family

ID=32984436

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054631A NO20054631L (no) 2003-03-10 2005-10-07 Antistoff mot tumorspesifikt antigen som mal

Country Status (19)

Country Link
US (4) US7855056B2 (ja)
EP (1) EP1602669B1 (ja)
JP (1) JP4462964B2 (ja)
KR (1) KR20050116374A (ja)
CN (2) CN1784426A (ja)
AT (1) ATE434044T1 (ja)
AU (1) AU2004220182B2 (ja)
BR (1) BRPI0408238A (ja)
CA (1) CA2518787A1 (ja)
DE (1) DE602004021567D1 (ja)
DK (1) DK1602669T3 (ja)
ES (1) ES2327408T3 (ja)
MX (1) MXPA05009715A (ja)
NO (1) NO20054631L (ja)
NZ (1) NZ542220A (ja)
RU (1) RU2345090C2 (ja)
TW (1) TW200508249A (ja)
WO (1) WO2004081050A1 (ja)
ZA (1) ZA200507298B (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200510282B (en) * 2003-07-02 2007-03-28 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
US20110195425A1 (en) * 2010-02-10 2011-08-11 Selinfreund Richard H Systems and methods for diagnosing parasite infections
EP2613380B1 (en) 2010-11-05 2015-03-18 LG Chem, Ltd. Enhanced-stability rechargeable battery
EP2589609A1 (en) * 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
US20140224373A1 (en) * 2013-02-12 2014-08-14 MPS Enterprises, Inc. Lay-flat hose for oilfield hydraulic fracturing operations
PT3204417T (pt) * 2014-10-10 2020-10-08 Innate Pharma Bloqueio de cd73
KR102665199B1 (ko) * 2018-11-15 2024-05-14 삼성디스플레이 주식회사 레이저 장치 및 이를 이용한 기판 식각 방법
WO2021072139A1 (en) * 2019-10-11 2021-04-15 Massachusetts Institute Of Technology Formulations for gastrointestinal delivery of oligonucleotides

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5792456A (en) * 1994-08-04 1998-08-11 Bristol-Myers Squibb Company Mutant BR96 antibodies reactive with human carcinomas
US5728821A (en) 1994-08-04 1998-03-17 Bristol-Myers Squibb Company Mutant BR96 antibodies reactive with human carcinomas
CA2280875C (en) * 1997-02-12 2005-07-05 Chugai Seiyaku Kabushiki Kaisha Remedies for lymphocytic tumors
AU752031B2 (en) 1998-05-08 2002-09-05 Toyama Chemical Co. Ltd. Novel spiro compounds or salts thereof, agent for preventing and/or treating autoimmune diseases and AP-1 inhibitors containing the same
HK1049014A1 (zh) 1999-07-29 2003-04-25 Medarex, Inc. 抗her2/neu的人类单克隆抗体
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
WO2002016603A2 (en) * 2000-08-21 2002-02-28 Millennium Pharmaceuticals, Inc. 23228, a novel human tetraspanin family member and uses thereof
US7361343B2 (en) 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US20030124579A1 (en) 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
EP1434881A4 (en) * 2001-09-17 2005-10-26 Protein Design Labs Inc METHOD FOR DIAGNOSIS OF CANCER COMPOSITIONS AND METHOD FOR SCREENING ON CANCER MODULATORS
US20070042360A1 (en) 2001-09-17 2007-02-22 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
NZ535925A (en) 2002-04-16 2008-06-30 Genentech Inc An isolated antibody that binds to a particular polypeptide
US7361342B2 (en) 2003-01-21 2008-04-22 Arius Research Inc. Cancerous disease modifying antibodies
US7393531B2 (en) 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
ZA200510282B (en) 2003-07-02 2007-03-28 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor

Also Published As

Publication number Publication date
ZA200507298B (en) 2006-06-28
WO2004081050A1 (ja) 2004-09-23
EP1602669A1 (en) 2005-12-07
JP2004290187A (ja) 2004-10-21
RU2005128277A (ru) 2006-06-10
AU2004220182A1 (en) 2004-09-23
NZ542220A (en) 2008-04-30
HK1078593A1 (en) 2006-03-17
US7741447B2 (en) 2010-06-22
US20080146785A1 (en) 2008-06-19
CA2518787A1 (en) 2004-09-23
US20070166312A1 (en) 2007-07-19
JP4462964B2 (ja) 2010-05-12
EP1602669B1 (en) 2009-06-17
NO20054631D0 (no) 2005-10-07
TW200508249A (en) 2005-03-01
DE602004021567D1 (de) 2009-07-30
MXPA05009715A (es) 2005-10-18
US20060127405A1 (en) 2006-06-15
US7855056B2 (en) 2010-12-21
CN1784426A (zh) 2006-06-07
ES2327408T3 (es) 2009-10-29
ATE434044T1 (de) 2009-07-15
DK1602669T3 (da) 2009-09-14
RU2345090C2 (ru) 2009-01-27
AU2004220182B2 (en) 2007-12-06
US20070025996A1 (en) 2007-02-01
US7361340B2 (en) 2008-04-22
CN102151334A (zh) 2011-08-17
BRPI0408238A (pt) 2006-03-01
KR20050116374A (ko) 2005-12-12
EP1602669A4 (en) 2006-08-09

Similar Documents

Publication Publication Date Title
WO2003080582A3 (de) Fredericamycin-derivate
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
BRPI0418745A (pt) anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente
CY1106386T1 (el) Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
WO2005062977A3 (en) Prostate cancer specific internalizing human antibodies
WO2006034455A3 (en) Polipeptide compounds for inhibiting angiogenesis and tumor growth
DE60332163D1 (de) Zusammensetzung zur hautaufhellung
CY1112953T1 (el) Χρηση των αντι-cd100 αντισωματων
WO2004080418A3 (en) Nucleic acid compounds for inhibiting angiogenesis and tumor growth
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
CY1108395T1 (el) Ουσια επαυξησης της δρασης εναντι ογκων και παραγοντας εναντι ογκων
NO20072290L (no) Organiske forbindelser.
BRPI0418589A (pt) composições farmacêuticas e métodos para tratamento por insulina
WO2006009765A3 (en) Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
ATE420099T1 (de) Medikament zur wachstumsinhibierung von tumoren
WO2004033666A3 (en) Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
NO20054631L (no) Antistoff mot tumorspesifikt antigen som mal
CY1110027T1 (el) Συνδυασμος ενωσεων πυριμιδυλαμινοβενζαμιδης και ιματινιβης για τη θεραπεια ή την προληψη των νεοπλασματικων ασθενειων
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
DE60227417D1 (de) Verwendung von emp9 zur prävention von proliferativen organerkrankungen
DE60310975D1 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus
DE10342747A1 (de) Pharmazeutischer Wirkstoff gegen Melanome

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application